NODULOCYSTIC ACNE
Conditions
Keywords
acne, nodulocystic, finasteride, 5 alpha reductase inhibitor
Brief summary
Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of once weekly, high dose oral finasteride compared to placebo for the treatment of severe nodulocystic acne in male subjects.
Detailed description
There will be 180 male subjects in this study. The study is composed of a Screening Period of up to 30 days during which inclusion / exclusion criteria will be reviewed, screening laboratory results will be obtained and medication washouts will be done as required. Subjects will complete the sexual function questionnaire and depression scale. A one day Baseline Period (Day 0), during which baseline assessments of acne lesion counts, physical examination and Investigator's Global Assessment Scale will be done. The Baseline Period will be followed by a 12-week randomized double-blind Treatment Period, in which subjects will be randomized into Finasteride 23.5 mg group, 33.5 mg group, or placebo group. During the Treatment Period, subjects will visit the study site Day 14, Day 28, and Day 56 for acne lesion counts and review of diaries, concomitant medications and adverse events. On Day 84 subjects will return to clinic for acne lesion counts and review of diaries, concomitant medications, adverse events and remaining study drug will be counted and collected. A physical exam and vital signs, Investigator Global Assessment, Subject Assessment of Efficacy, depression scale and sexual function questionnaire will be completed before the subject is discharged from the study.
Interventions
DRUGFinasteride 23.5 mg tablets
DRUGFinasteride 33.5 mg tablets
DRUGPlacebo tablets
Sponsors
Elorac, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subject voluntarily agrees to participate in this study and signs an IRB-approved informed consent prior to performing any of the screening procedures. 2. Males 18 years to 35 years of age. 3. Except for severe nodulocystic acne, subject is in generally good health. 4. Ten (10) or more nodular lesions (facial and/or truncal). 5. Weight between 40 and 110 kg. 6. No significant disease or clinically significant finding in a physical examination. 7. No clinically significant abnormal laboratory value. 8. No clinically significant abnormal vital sign measurement. 9. Subject is able to swallow pills. 10. Subject agrees to use a medically acceptable form of barrier-method contraception (e.g. condoms with spermicide or abstinence). 11. Subject is willing and able to cooperate to the extent required by the protocol.
Exclusion criteria
1. Female subjects will be excluded from the study. 2. Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), pyoderma faciale, sinus tracks. 3. Subject with a wash out period from Baseline for topical treatment on the skin less than: Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatment (2 weeks); Cosmetic procedures (1 week); Photodynamic therapy and laser therapy for acne (3 months). 4. Subject with a washout period from Baseline for systemic treatment less than: Corticosteroids, antibiotics (4 weeks), spironolactone (3 months), other systemic acne treatments (6 months), cyproterone acetate (6 months), lithium, anticonvulsants, barbiturates, androgenic and anabolic steroids, testosterone, estrogen, anti-tuberculous drugs, cyclosporine, and azathioprine (6 months), surgical treatment of acne (12 months), finasteride or other 5α-reductase inhibitors (12 months). (Table 2) 5. Subjects with current or history of prostatic disease including benign prostatic hypertrophy, or surgery on prostate. 6. Known history or presence of any clinically significant unstable medical condition(s) which in the opinion of the investigator could pose a risk for the safety of the subject, e.g. diabetes, cardiovascular, liver or kidney disease. 7. Subjects with any skin disease or other condition that might interfere with the evaluation of nodular acne. 8. Known history or suspected carcinoma. 9. Allergy to finasteride or any other ingredients in the study medications. 10. Subjects with history in past 12 months of active addiction, abuse, misuse and/or dependence on drugs or alcohol. 11. Use of investigational drug within 90 days prior to Day 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acne Nodular Lesion Count | 12 Weeks | Change from Baseline to week 12 in the total number of nodular lesions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects who achieve at least a 75% reduction in total number of nodular lesions | 12 Weeks | Change from Baseline to week 12 in the total number of nodular lesions |
| Investigator's Global Assessment Scale of Acne Severity | 12 Weeks | Change from Baseline to week 12 |
| Non-Inferiority (NI) for non-nodulocystic inflammatory lesions | 12 Weeks | The NI bound will be larger of 10% reduction or a count of 4 lesions. |
| Change in total number of nodular lesions. | 2, 4, and 8 weeks | Change from baseline to weeks 2, 4 and 8. |
| Proportion of subjects with 2 category improvement on Investigator's Global Assessment Scale | 12 Weeks | Change from Baseline to week 12 |
Countries
United States
Outcome results
None listed